Biotechnology

Cape Fear BioCapital's new fund isn't just about capital. It's a strategic infusion of operator experience and partnerships set to transform NC's biotech landscape.

As advanced therapies reshape medicine, the race to control their complex supply chains heats up. Resonant's latest acquisition places it at the heart of Europe's booming market.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Northway Biotech's new Vilnius hub isn't just a factory; it's a strategic move to dominate Europe's advanced therapy market. A deep dive into the investment.

Facing delisting, BioRestorative executes another reverse split. We dive into whether this financial maneuver can sustain it or just delays the inevitable.

The prestigious Prix Galien awards debut in Seoul, cementing South Korea's status as a life sciences leader and spotlighting a wave of homegrown innovation.

Drs. Zoghbi and Bird win the prestigious Horwitz Prize for turning Rett syndrome from an untreatable mystery into a reversible condition, offering new hope.

As Stoke prepares for a key investor conference, its lead drug zorevunersen nears a pivotal Phase 3 readout, promising a new era for patients and the RNA platform.

A new deal between Owkin and Boehringer Ingelheim isn't just a partnership; it's a look at the future where AI scientists and deep data drive innovation.

A new US patent allowance for Purple Biotech's modular CAPTN-3 platform bolsters its strategic position, promising safer, more precise antibody cancer treatments.

Resalis Therapeutics poaches a top clinical leader from Novo Nordisk to steer its novel RNA-based obesity drug, RES-010, through clinical trials.

Thai researchers are turning fat into insulin-producing cells to cure pet diabetes. But can this breakthrough navigate the path from lab to leash?

As iBio heads to a key investor conference, its AI-driven antibody platform aims to solve the GLP-1 paradox: achieving sustainable weight loss by preserving muscle.

A biotech startup is targeting a hidden cause of chemo resistance. An AI firm claims it can predict a drug's success. Their deal is a major market signal.

With new data on its recently approved therapy TREGZI™, Orca Bio aims to shift the goal of cancer transplants from mere survival to a life free of complications.

As RNA drugs boom, a critical bottleneck emerges: quality control. A San Diego firm's new tool promises to deliver a complete picture, speeding up development.

PeptidePrices' new market intelligence platform brings radical transparency to the chaotic online peptide market, centralizing data to empower researchers.

Adicet Bio nears a pivotal data readout for its lupus CAR-T, now viable for outpatient use, while launching a novel solid tumor attack in prostate cancer.